Understanding biology – Improving outcomes
The aim of this meeting is to focus on some of the major challenges that are confronting clinicians and scientists in the current efforts to develop and implement novel drugs in cancer treatment, and to discuss recent developments that may provide strategies to overcome obstacles to therapeutic progress. A faculty of internationally renowned leaders in their respective fields will present their insights and provide a forum for in-depth discussion.
Scientific Steering Committee: Thoralf Christoffersen, Steinar Aamdal, Olav Dahl, Vasanti Natarajan
Supported by Roche Norge.
09.00−09.20 Welcome and introduction
Thoralf Christoffersen, University of Oslo, Norway
09.20−10.20 Tumour metastasis: moving new biological insights into the clinic
Yibin Kang, Princeton University, USA
10.20−10.40 Refreshment break
10.40−11.40 Strategies to overcome resistance to targeted therapies
Pasi Jänne, Harvard Medical School, USA
11.40−12.40 Tumour heterogeneity and the implications for targeted therapies
Charles Swanton, University College London, UK
13.30−14.30 Immunotherapy: are we ready for prime-time?
Drew Pardoll, Johns Hopkins University, USA
14.30−15.40 Keynote lecture: Re-engineering the tumour microenvironment to enhance
cancer treatment – from bench to bedside to biomarkers
Rakesh Jain, Harvard Medical School, USA
15.40−16.00 Refreshment break
16.00−17.30 Open discussion – clinical implications of new interventions
Moderators: Olav Dahl, Haukeland University Hospital and Steinar Aamdal, University of Oslo, Norway
17.30−17.40 Summary and close
Vasanti Natarajan, Group Medical Lead, Roche, Norway
17.40 Meeting end: transfer to dinner location (Gamle Logen)